Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, proudly announces a strategic leadership restructuring, setting the stage for the company’s continued growth and commitment to delivering unparalleled results for its clients.

After three highly successful years of guiding EvidentIQ’s evolution and establishing it as a formidable player in the healthcare industry, Andreas Weber will step down from his role as CEO to focus on leading the Sales efforts. With his wealth of experience in the market, Andreas will be instrumental in driving the Sales team to new heights and achieving even greater success.

Dr. Dominique Manu, a seasoned professional with over 15 years of leadership experience in various sectors, including successfully transforming a CRO to become one of the digital market leaders in the industry in his last CEO engagement, will take over the position of CEO at the EvidentIQ Group. This strategic move underscores EvidentIQ’s dedication to optimizing its leadership structure to align with its expanding portfolio and ambitious goals.

"As EvidentIQ’s goals and offerings become richer and more complex, the leadership needs to adapt with roles and additional management capacities to facilitate our growth trajectory," explained Dominique. Our markets are changing, and we are determined to meet the evolving needs of our clients and further solidify our position as the most innovative solution provider."

Dominique has a proven track record of success in driving performant innovation, fostering strategic partnerships, and accelerating growth for companies operating in highly regulated industries. His understanding of the clinical trial landscape, digital transformation and strong business acumen make him the ideal choice to lead EvidentIQ into its next phase of development. Commenting on the collaboration, Dominique also expressed, "I am thrilled to join a global group with a unique technology stack and a rigorous focus on customer solutions that is unmatched in the clinical trial sector. Together, we will propel EvidentIQ towards achieving new milestones and expanding our footprint in the market by combining smart technology with integrated data solutions and AI.”

Dominique’s visionary leadership, combined with Andreas’s market knowledge, creates a winning formula that boosts confidence within the organization and among stakeholders. With this change, EvidentIQ is set to maintain its leading position in the tech industry, revolutionizing how businesses leverage cutting-edge solutions for growth and success.

As EvidentIQ embarks on this transformative journey, the company remains committed to providing innovative solutions that empower clients to thrive in an ever-evolving landscape. With a strong leadership team and dedicated employees, EvidentIQ is poised to reach new heights, deliver exceptional value to clients, and leave a lasting impact on the tech and health industries. 

Über die EvidentIQ Group GmbH

EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.

EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.

Firmenkontakt und Herausgeber der Meldung:

EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com

Ansprechpartner:
Gilda Teissier
Global Marketing Director
E-Mail: gilda.teissier@evidentiq.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel